Market Overview - U.S. stocks showed mixed performance with the Dow Jones index decreasing by approximately 0.1% to 48,698.11, while the NASDAQ increased by 0.12% to 23,641.67 and the S&P 500 rose by 0.11% to 6,939.71 [1] - In the sector performance, information technology shares rose by 0.4%, while industrials stocks fell by 0.2% [1] Company News - Biohaven Ltd. (NYSE:BHVN) shares declined after the company reported that its Phase 2 study for BHV-7000, aimed at treating major depressive disorder, did not meet its primary endpoint as measured by the Montgomery Åsberg Depression Rating Scale [2] - A SPAC III Acquisition Corp (NASDAQ:ASPC) saw its shares surge by 82% to $24.38 [8] - Davis Commodities Limited (NASDAQ:DTCK) shares increased by 77% to $0.4209 following the release of its first-half fiscal unaudited financial results [8] - ECD Automotive Design, Inc. (NASDAQ:ECDA) shares rose by 57% to $1.2338 after announcing an expansion of its product lineup for 2026 [8] - Aptevo Therapeutics Inc. (NASDAQ:APVO) shares fell by 31% to $0.6451 due to a 1-for-18 reverse stock split [8] - Kaival Brands Innovations Group, Inc. (NASDAQ:KAVL) shares decreased by 12% to $0.1360 [8] - Kandal M Venture Limited (NASDAQ:FMFC) shares dropped by 12% to $0.3450 after a previous increase of over 28% [8] Commodity Market - In commodity trading, oil prices fell by 0.4% to $58.14, while gold prices increased by 1.2% to $4,555.30 [4] - Silver prices decreased by 4% to $74.515, whereas copper prices rose by 3% to $5.7445 [4] European Market - European shares exhibited mixed results with the eurozone's STOXX 600 gaining 0.1%, while Spain's IBEX 35 Index fell by 0.1% [5] - London's FTSE 100 decreased by 0.19%, Germany's DAX 40 rose by 0.23%, and France's CAC 40 slipped by 0.01% [5] Asian Market - Asian markets closed mixed with Japan's Nikkei 225 gaining 0.68%, China's Shanghai Composite rising by 0.10%, and India's BSE Sensex falling by 0.43% [6]

Core Insights - 100% of patients in Cohorts 1-3 remain free of cytokine release syndrome, indicating a strong safety profile for the CD3 design used in the study [1] - The study evaluates mipletamig, a CD123 x CD3 bispecific molecule, in combination with azacitidine and venetoclax for newly diagnosed acute myeloid leukemia patients unfit for intensive chemotherapy [1] - Preliminary results were presented at the American Society of Hematology Annual Meeting, highlighting the potential of the ADAPTIR™ and ADAPTIR-FLEX™ platform technologies developed by the company [1] Company Summary - Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics [1] - The company utilizes proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies in its research and development efforts [1] Industry Context - The ongoing Phase 1b/2 RAINIER study is significant for the treatment of acute myeloid leukemia, particularly for patients who cannot undergo intensive chemotherapy [1] - The combination of mipletamig with standard treatments like azacitidine and venetoclax represents a potential advancement in the therapeutic options available for AML [1]

Core Insights - Aptevo Therapeutics is actively participating in several key financial, industry, scientific, and medical conferences this fall to showcase its ongoing developments and momentum in the biotechnology sector [1] Conference Participation - Aptevo will participate in the 4th Annual ROTH Healthcare Opportunities Conference on October 9, 2025, discussing its lead asset mipletamig and its clinical progress in Acute Myeloid Leukemia (AML) [1] - The company will also be present at the Biotechnology Innovation Organization (BIO)-Europe 2025 from November 3-5, 2025, engaging in meetings at the largest biotechnology event in Europe [1] - At the Society of Immunotherapy in Cancer (SITC) 2025, scheduled for November 5-9, 2025, Aptevo's R&D team will present a poster on a novel trispecific targeting approach to address the immunosuppressive tumor microenvironment [1] - The interim results from the ongoing Phase 1b/2 RAINIER trial evaluating mipletamig in frontline combination therapy for AML will be presented at the American Society of Hematology (ASH) 2025 meeting from December 6-9, 2025 [1]

Market Overview - U.S. stocks traded mostly higher, with the Nasdaq Composite gaining over 100 points on Thursday [1] - The Dow decreased by 0.04% to 46,000.59, while the NASDAQ rose by 0.49% to 22,370.12 and the S&P 500 increased by 0.29% to 6,619.34 [1] Sector Performance - Information technology shares increased by 0.8% on Thursday [1] - Materials stocks fell by 0.7% [2] Economic Indicators - U.S. initial jobless claims declined by 33,000 to 231,000 in the second week of September, better than market estimates of 240,000 [3][9] - The Philadelphia Fed Manufacturing Index rose to +23.2 in September, the highest level since January, compared to -0.3 in August [11] Commodity Prices - Oil prices increased by 0.5% to $64.37, while gold decreased by 0.4% to $3,701.70 [6] - Silver fell by 0.1% to $42.110 and copper dropped by 0.5% to $4.6135 [6] International Markets - European shares were higher, with the eurozone's STOXX 600 rising by 0.8% [7] - Asian markets closed mixed, with Japan's Nikkei gaining 1.15% and Hong Kong's Hang Seng falling by 1.35% [8] Company News - 89bio, Inc. shares surged 85% to $14.97 after announcing an acquisition agreement with Roche [10] - Aeries Technology, Inc. shares also rose 85% to $1.0500 following a partnership announcement with an annual contract value of up to $8 million [10] - Aptevo Therapeutics Inc. shares increased by 57% to $2.2201 after breakthrough clinical results [10] - Replimune Group, Inc. shares dropped by 40% to $3.4288 as the company evaluates FDA feedback [10] - BioCardia, Inc. shares fell by 34% to $1.02 after announcing a public offering and trial results [10] - Office Properties Income Trust shares decreased by 28% to $0.4066 [10]

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential trading opportunities before the market opens [1] Premarket Gainers - 89bio, Inc. (ETNB) increased by 83% to $14.84 [3] - Aptevo Therapeutics Inc. (APVO) rose by 75% to $2.47 [3] - Psyence Biomedical Ltd. (PBM) saw a 29% increase to $4.82 [3] - Beam Global (BEEM) gained 27% reaching $3.23 [3] - MicroAlgo Inc. (MLGO) was up 14% at $13.06 [3] - Akero Therapeutics, Inc. (AKRO) increased by 12% to $47.50 [3] - Hyperion DeFi, Inc. (HYPD) rose by 11% to $13.69 [3] - Sonnet BioTherapeutics Holdings, Inc. (SONN) increased by 11% to $7.85 [3] - FuelCell Energy, Inc. (FCEL) was up 9% at $8.34 [3] - Robo.ai Inc. (AIIO) gained 6% to $2.05 [3] Premarket Losers - Presidio Property Trust, Inc. (SQFT) decreased by 14% to $7.58 [4] - Aeluma, Inc. (ALMU) fell by 10% to $15.18 [4] - FGI Industries Ltd. (FGI) dropped 10% to $7.65 [4] - Lazydays Holdings, Inc. (GORV) was down 9% at $2.26 [4] - StableX Technologies, Inc. (SBLX) decreased by 8% to $5.40 [4] - Artelo Biosciences, Inc. (ARTL) fell by 8% to $4.48 [4] - SciSparc Ltd. (SPRC) decreased by 8% to $4.10 [4] - Cracker Barrel Old Country Store, Inc. (CBRL) was down 7% at $45.75 [4] - Columbus Circle Capital Corp I (BRR) fell by 7% to $9.42 [4] - Visionary Holdings Inc. (GV) decreased by 7% to $2.58 [4]

Shares of Bullish BLSH rose sharply in pre-market trading after the company posted a profit for the second quarter after Wednesday's closing bell.Bullish reported quarterly earnings of 93 cents per share, versus a year-ago loss of $1.03 per share. The company reported $58.63 million in revenue, which is up from revenue of $49.57 million from the same period last year.Bullish shares jumped 12.3% to $60.90 in the pre-market trading session.Here are some other stocks moving in pre-market trading.Gainers89bio, ...

Core Viewpoint - The article highlights significant movements in the Hong Kong and US stock markets, focusing on various companies' performances and the impact of regulatory changes on specific sectors. Group 1: Hong Kong Stock Market Highlights - Haitian Flavoring (03288) debuted with over a 3% increase, raising HKD 10 billion and holding a 6.2% global market share in soy sauce, leading the Chinese seasoning market with a 4.8% share [1] - Stablecoin concept stocks surged, with Lianlian Digital up 11%, Yika up 9%, and Zhong An Online up 8%, driven by the implementation of Hong Kong's stablecoin regulations [1] - Hezhima Intelligent (02533) rose over 3% as it plans to acquire an AI chip company to expand its automotive and edge AI product lines [1] - Delin Holdings (01709) increased over 3% with an expected annual profit growth of 10%-30% (to HKD 110-130 million) and its subsidiary Synaptic Technology securing tens of millions in A-round financing [1] - Jingtai Technology (02228) saw over a 4% rise, producing its first clinical candidate drug, PRMT5 inhibitor PE-0260, with clinical trials set to start in the second half of 2025 [1] - Gold stocks collectively fell, with Lingbao Gold and Zhu Feng Gold both down 4%, affected by a pullback in spot gold prices [1] - Innovent Biologics (01801) rose over 4% after obtaining global rights for GlycoT's ADC technology, with positive outlooks for IBI363/343's international potential [1] - Longpan Technology (02465) increased over 6% due to policy support accelerating solid-state battery industrialization, with the Ministry of Industry and Information Technology allocating HKD 6 billion for special research [1] Group 2: Other Notable Movements - Simor International (06969) fell over 5% as shareholder Yiwei Lithium Energy announced a third reduction of 3.5% in its stake, dropping to 27% and losing control [2] - Fubo Group (03738) rose over 4% due to favorable policies for data asset REITs, with the company targeting annual AI business revenue in the million-dollar range [2] - Yadea Holdings (01585) increased over 4% with a projected 55% rise in H1 net profit to HKD 1.6 billion, driven by new national standards enhancing industry concentration [2] - Perfect Medical (01830) fell over 6% as medical beauty consumption shifted to Shenzhen and South Korea, with an expected 35% decline in annual profit [2] - Yunbai International (00030) surged over 15% after acquiring global distribution rights from its parent company Yunnan Baiyao, covering a full range of products including medicines and personal care [2] - Luk Fook Holdings (00590) dropped over 4% due to increased gold hedging losses from rising gold prices and high base effects from last year's acquisition of King of Gold [2] Group 3: US Stock Market Highlights - Brain Regen Technologies (RGC.US) fell over 18% after a 400% increase in the previous two days, as profit-taking occurred; the company focuses on liquid formulations for ADHD and autism [3] - Marvell Technology (MRVL.US) rose over 7% after announcing a collaboration to develop AI power solutions and launching a 2nm custom SRAM chip with leading bandwidth and energy efficiency [3] - Circle (CRCL.US) surged over 33% after the US Senate passed a stablecoin bill, boosting the stock's value by 410% since its listing [3] - The rare earth sector continued to rise, with MP Materials up 4.9% and USA Rare Earth up 5.58%, driven by policy support for strategic resource demand [3] - Wolfspeed (WOLF.US) fell over 30% amid reports of a potential bankruptcy agreement, despite the silicon carbide market projected to reach USD 29 billion by 2030 [3] - Odyssey Marine (OMEX.US) rose over 11% after Trump signed an executive order to expedite deep-sea mining permits, with a 93% increase year-to-date [3] - Huya (HUYA.US) increased over 3% as the "HYPER eSports Carnival" is set to open in Chengdu, boosting platform traffic and commercialization expectations [3] Group 4: Additional Notable Movements - AST SpaceMobile (ASTS.US) rose over 10%, with an 85% increase in June, partnering with Vodafone India to provide satellite connectivity to unconnected areas [4] - Arqit Quantum (ARQQ.US) surged over 22% after being selected for Oracle's defense ecosystem, highlighting the strategic value of quantum encryption technology [4] - Aptevo (APVO.US) skyrocketed over 81% due to a new leukemia drug showing an 85% response rate in frontline treatment [4] - Upstart (UPST.US) rose over 10% after Bank of America raised its target price to USD 56, maintaining a "hold" rating as the credit tech platform's valuation recovers [4] - Coinbase (COIN.US) increased over 16% as it plans to apply to the SEC for "tokenized stocks," opening new growth opportunities in traditional equity on-chain [5]

Market Performance - U.S. stocks showed positive movement with the Dow Jones index increasing by over 150 points, up 0.36% to 42,366.99 [1] - The NASDAQ rose 0.56% to 19,629.54, and the S&P 500 gained 0.39% to 6,006.14 [1] - Consumer discretionary shares increased by 0.6%, while energy stocks fell by 0.4% [1] Company Earnings - Korn Ferry (KFY) reported better-than-expected fourth-quarter fiscal year 2025 results, with adjusted earnings per share of $1.32, surpassing the analyst consensus estimate of $1.26 [2] - Quarterly sales reached $719.83 million, exceeding the expected $689.90 million [2] Commodity Prices - Oil prices decreased by 0.9% to $74.20, while gold prices increased by 0.1% to $3,410.40 [5] - Silver prices fell by 0.5% to $36.970, and copper prices rose by 0.8% to $4.8455 [5] Global Market Trends - European shares were mixed, with the eurozone's STOXX 600 declining by 0.4%, while Spain's IBEX 35 Index rose by 0.1% [6] - Asian markets closed mixed, with Japan's Nikkei gaining 0.90% and Hong Kong's Hang Seng Index falling by 1.12% [7] Stock Movements - Ryde Group Ltd. (RYDE) shares surged by 165% to $0.4719 following the announcement of a 40% stake acquisition in Atoll Discovery [9] - Aptevo Therapeutics Inc. (APVO) shares increased by 114% to $6.06 after positive clinical data from its ongoing trial [9] - Eyenovia, Inc. (EYEN) shares dropped by 37% to $4.4100 due to the appointment of a strategic advisor and debt agreement amendments [9]